Prof. Dr. Mathias Heikenwälder is a trained molecular biologist, with expertise in immunology and a strong link to translational research evoked by 10 years of work and expertise in a Pathology Institution (Clinical Pathology, University Hospital Zurich). Since October 2015 he is Department head at the German Cancer Research Center (DKFZ) in Heidelberg focusing on the link between chronic inflammation and cancer. Since October 2022 he is director of the M3 Research Center, University Tübingen. Prof.

Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist working within the Department of Surgery and Cancer at Imperial College in London. <br><br>He is Director of Developmental Cancer Therapeutics at Imperial College, where he leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy.

Dr. Schnabl is a trained gastroenterologist and physician-scientist. He is Professor of Medicine in the Department of Medicine at the University of California San Diego, founding Director of the NIH-supported San Diego Digestive Diseases Research Center (SDDRC) and Director of Research for the Division of Gastroenterology. His research focus is to understand the complex multi-directional interactions that occur between the gut microbiota and the liver.

Dr. Akiyama is an Associate Professor of Medicine and Clinician-Investigator at Albert Einstein College of Medicine and Montefiore Medical Center. In addition to providing care and treatment to people living with HIV, HCV, and substance use disorders, Dr. Akiyama conducts research focusing on models of care for HCV, HIV, and other infectious diseases in resource limited settings, with a particular focus on the criminal legal system. Dr.

Dr. Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is currently a Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and holds an honorary professor position at the University of Bristol. She is the vice president of the International Network of Hepatitis and Health in Substance Users (INHSU).

Catherine Chappell is an Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh. She is board certified in Obstetrics and Gynecology, Addiction Medicine and Complex Family Planning. Her research focuses on the evaluation of direct-acting antivirals for HCV in pregnancy.

Dr. Fierer received his medical degree from Yale University and his Infectious Diseases training at the National Institutes of Health. In 2006, he and his team at Mount Sinai uncovered the epidemic of HCV infection among men who have sex with men with HIV in New York City.

David A. Brenner, M.D. Professor and President and CEO<br>Research. My research program's general approach is to start with mouse models of chronic liver injury that reflect the different type of human diseases; common bile duct ligation (cholestatic liver disease), carbon tetrachloride administration (toxicant liver injury, (TASH)), intragastric alcohol feeding (alcoholic liver disease, (ASH)), and diet induced obesity, choline deficient amino acid supplemented diet, and Foz/Foz mice or mup-UPA with high fat diet (non-alcoholic steatohepatitis (NASH)).

Dr. Kathleen Corey is the Director of the Massachusetts General Hospital (MGH) Non-Alcoholic Steatotic Liver Disease Program and an Associate Professor of Medicine at Harvard Medical School (HMS).<br>She is a hepatologist who specializes in MASLD and a Physician Investigator in the Clinical and Translational Epidemiology Unit at MGH.

Leila Gobejishvili is Associate Professor in the Department of Physiology at the University of Louisville, Louisville, Kentucky. She received her PhD in Biology from the Institute of Physiology, Georgian Academy of Sciences, Tbilisi, Georgia in 1995. In 2001 she joined Dr. Craig McClain's liver research group. Her first project examined the mechanisms of alcohol mediated "priming" of monocytes/macrophages to produce higher levels of inflammatory cytokines in response to endotoxin.